Key result
Device-based therapies show potential for resistant hypertension but need larger randomized trials before routine use.
Why the study?
Secondary and resistant hypertension remain challenging conditions, prompting the development and evaluation of novel device-based therapies.
Device-based therapies such as renal denervation and baroreflex activation offer promising alternatives for resistant hypertension, though larger randomized controlled trials are needed before routine clinical adoption.
Should not yet change practice in resistant hypertension; leaves open definitive role pending large RCTs.
Introduction: Hypertension is the leading cause of death in the cardiovascular system. Indeed, untreated hypertension can affect one's general health, but medicine can help hypertensive people reduce their chance of developing high blood pressure. However, secondary hypertension remains an unresolved illness. Areas covered: This review will go through the typical and unusual device-based therapies for resistant hypertension that have arisen in recent years. Further to that, the innovations developed in device-based RH treatment will be covered, as well as the research and studies assessing these novel technologies. Expert opinion: The innovative device-based techniques that target resistant hypertension provide a potential therapy that has been backed by a number of studies and clinical trials, whereas pharmacological non-adherence and increased sympathetic activity are recognized to be the primary causes of resistant hypertension. Nevertheless, some limitations will be critical for the future of these RH systems, with the device's design and larger RCTs playing a significant role in determining whether a position in routine treatment could be warranted.
No takes yet. Share an insight, caveat, or question.
Jami et al. (2024) conducted a review in Resistant hypertension. Device-based therapies for resistant hypertension was evaluated. Innovative device-based techniques, particularly renal denervation and baroreflex activation therapy, provide a potential therapeutic alternative for resistant hypertension but require larger randomized controlled trials for routine clinical use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: